Drugs cost too much. There is a better way to fund medical innovation

Drugs Medicine 2018 United Nations

UNICEF/Olivier Asselin In Côte d’Ivoire, a counsellor from UNICEF partner NGO Femme Active, instructs an adolescent boy, diagnosed with HIV in 2012, on how to take his antiretroviral (ARV) medication correctly.

This article is brought to you based on the strategic cooperation of The European Sting with the World Economic Forum.

Author: Rufus Pollock, Lead, iMed Project, and Founder and President of Open Knowledge

Drugs are expensive. Very expensive, and becoming ever more so, it seems. Prices for new medicines have been steadily rising for the past few decades. It costs a great deal to bring new drugs to market, the explanation goes, and without high prices, the pipeline of new medicines will run dry.

This argument is unsustainable, especially when even the world’s most developed economies and healthcare systems are struggling to afford vital medicines. To keep paying more for drugs simply cannot be the answer. Bad health affects everyone. We should be urgently seeking new mechanisms of funding medical innovation that do not compromise on access.

There is a strong moral and social obligation for exploring alternatives. Millions of people globally do not have access to the medicines they need to survive. In the US, millions of adults skip prescribed medications due to the high cost. The same is true in Canada, where the public healthcare system does not usually extend to cover prescription medicines, and in Europe, especially in poorer members of the EU.

The situation is worse in less developed countries. Many pay out of pocket for drugs, and the hefty price tags can run many times the annual average income. Two widely used drugs for treating hepatitis C cost the equivalent of one or more years’ average earnings in 12 out of 30 countries, revealed a recent study by the World Health Organization. Millions are dying because they cannot afford the medicine they need to stay alive.

When some members of society lack medicine, there are consequences beyond the individual directly affected. The increased morbidity caused by a lack of access to medication places an extraordinary strain on healthcare systems, exacerbating the drain on their resources from ever more expensive drugs. In addition, unhealthy populations are far less economically productive than healthy ones. Beyond social justice, there are clear economic reasons to find new models of funding medical innovation that do not restrict access to medicine.

The current state of affairs is making the world a more dangerous place. Healthcare systems that are strained by increased morbidity, and by a critical lack of money and medicine, are less likely to be able to contain outbreaks when they occur. Poor global health increases global instability. Failing to ensure everyone has access to necessary medication can have profound knock-on consequences and worsen existing crises.

Moreover, the high sale price of drugs skews incentives for innovation towards wealthy consumers. This means that vital medicines for certain ailments are not accessible when needed on a global scale. For instance, the Ebola virus had been known about for decades before the recent outbreak, and yet virtually no treatments were available. The whole world is unprepared and at risk.

The explanation that pharmaceutical companies offer for high drug prices is compelling. It costs a great deal of money to bring a drug to market, they argue. This is why so many reluctantly accept the current state of affairs, in which innovation justifies restricted access. Though it is true that drugs do cost a lot to bring to market, there is a remarkable lack of consensus on exactly how much.

This is compounded by a systemic lack of transparency. It is often not known how much is spent on what, and how reliant private-sector developments are on publicly funded research. Often, medicines that are developed with significant help from public funds do not reflect that support in prices, and there is no guarantee under the monopoly rights patent system that they should.

Moreover, a great deal of money that could be earmarked for research is spent on marketing instead. Indeed, in some large drug companies, expenditure on marketing outweighs that on research.

This model is unsustainable. So long as we continue to reward innovation through a single channel – buying the drug – access to new medicines will be limited. Ultimately, the problem is about how we pay for medicine. Today, we only pay by purchasing the end product. This means that the costs of manufacture (which is cheap) and innovation (which is expensive) are rolled into one. This puts access and innovation in conflict.

If we were to change how we fund medicines, there could be no conflict. Incentives for innovation and access to affordable drugs could co-exist. We can fund research and production separately. There is no excuse for not exploring the wide systemic changes needed to make that happen.

Today’s model is unsustainable, unhealthy and utterly unnecessary. We can have new medicines and wide access to them. We should be working towards this as a matter of urgency.

And we have ideas. For example, at the iMed Project we’ve been developing innovative two-part payment models for funding medicines that would maintain incentives for innovators while making treatment at cost of manufacture.”

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Advertising

Featured Stings

Who will win the AI race? If countries work together, then the answer could be all of us

Europe on the Move: Commission completes its agenda for safe, clean and connected mobility

90% of fish stocks are used up – fisheries subsidies must stop

Everyone has ‘a moral imperative’ to uphold the rights of persons with disabilities, says UN chief

EU leads the torn away South Sudan to a new bloody civil war

‘Habitual residence’ rules deprive EU workers from social benefits

EU Parliament and Council: Close to agreement on the bank resolution mechanism

Brexit negotiations: back to square one, tougher words, no good faith

EU unfolds strategy on the Egypt question

“If the job market doesn’t exist, then even the most brilliant Youth Guarantee cannot ensure a job to these young people”, European Youth Forum Secretary General Giuseppe Porcaro on another Sting Exclusive

The importance of pre-departure training for a better understanding of global health issues

Beware the fragility of the global economy

New skills agenda for Europe needs real investment

More solidarity and interaction between generations needed to challenge age stereotypes and ingrained ageism

“We have to do a better job of creating alternatives to violent extremism”, US Secretary of State John Kerry from Switzerland; the Sting reports live from World Economic Forum 2015 in Davos

Mood changes in Europe in favour of growth and jobs

8000 young people in the EP in Strasbourg: “a breath of fresh air for EU democracy”

EU Commission draws the wrong conclusions

The UK to split if May’s hard or no-deal Brexit is pursued

Alarming level of reprisals against activists, human rights defenders, and victims – new UN report

Can Kiev make face to mounting economic problems and social unrest?

A Sting Exclusive: “Climate change and youth inaction: oblivion or nonchalance?”, AIESEC wonders from Brussels

Act now to end violence, Zeid urges Nicaraguan authorities

Why EU’s working and unemployed millions remain uncertain or even desperate about their future

The financial sector cripples Eurozone growth prospects

Why are the financial markets shivering again?

Switzerland to introduce strict restrictions on executive pay

Bankruptcy or referendum: which one is going to be first?

Nuclear non-proliferation treaty an ‘essential pillar’ of international peace, says UN chief

These coastal countries are sinking the fastest

“Is Europe innovative? Oh, Yes we are very innovative!”, Director General of the European Commission Mr Robert-Jan Smits on another Sting Exclusive

Migration Crisis: how to open the borders and make way for the uprooted

On the detention of children in the United States of America

Is Eurozone heading for disinflation?

Copyright: European Union , 2017; Source: EC - Audiovisual Service; Photo: Frank Molter

EU hits deadlock on the future of glyphosate a month before deadline

Eurozone: Sovereign debt decreases for the first time since 2007

COP21 Breaking News_03 December: Argentina Accepts KP Amendment

A reflection of health inequity in recent epidemics

Intel @ European Business Summit 2014: Better decisions now, the new business dashboard 

MEPs to vote on overhaul of road transport rules in July

Crimea, a wicked game of political chess and a ‘big’ coincidence

So, what is your favourite Sustainable Development Goal?

Q&A on the 19th China-EU Summit to be held on 01-02 June 2017 in Brussels

Hollande decisively rebuffs Merkel’s and Rehn’s austerity policies

EU and Japan agree on free-trade deal and fill the post-TPP void

Why medicine is relevant to the battle against climate change

Climate change update: will the UN member states regain momentum despite the little progress at COP23?

Global health challenges require global medical students

WEF Davos 2016 LIVE: “If we do not do properly the Paris agreement, then all 16 remaining goals will be undermined”, UN Secretary General Ban Ki-moon cautions from Davos

Youth employment crisis easing but far from over

“A divided Europe is not in China’s interests”, Ambassador Zhang of the Chinese Mission to EU welcomes Brussels

The Changing Scope of International Economic Relations – Chinese Leadership in the 21st Century

ZTE @ MWC14: ZTE excels in all areas at this year’s Mobile World Congress

The gender gap of medicine in 2018

The IMF overstates the risks for Eurozone and downgrades the threats for the US economy

Conflicting statistics and bad banks haunt the Eurozone

Utmost hypocrisy emitted by EU’s energy regulation

How secure is blockchain?

Juncker Investment Plan for Europe welcomed by European Youth Forum

Eurasian Union begins: the giant modelled on the EU is Moscow’s biggest challenge

More Stings?

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s